Improvement in Quality of Life with OnabotulinumtoxinA for Cervical Dystonia: POSTURe
Authors:
Open Access
- 21 December 2020
- journal article
- research article
- Published by Cambridge University Press (CUP) in Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
- Vol. 48 (5) , 676-684
Abstract
Introduction: Symptoms of cervical dystonia (CD) can vary in severity and cause significant pain. OnabotulinumtoxinA is an approved treatment for CD. This study assessed health-related quality of life (HRQoL) in patients with CD who received multiple onabotulinumtoxinA treatments.Methods: This prospective, observational standard-of-care study was conducted at multiple neurology centers in Québec, Canada. Patients reported the health impact of CD using the Cervical Dystonia Impact Profile (CDIP)-58, before and after up to eight onabotulinumtoxinA treatments. Other measures included the Cervical Dystonia Severity Rating Scale by physician, employment status using the Work Productivity Questionnaire and pain using the Pain Numeric Rating Scale (PNRS). Adverse events (AEs) were recorded.Results: Sixty-two patients were enrolled (safety population, n = 61; modified efficacy population, n = 58). Participants were mostly females who were employed; most (79.3%) had torticollis. In all, 21/62 patients (33.9%) discontinued the study. At the final visit, there was a statistically significant (p < 0.001) improvement in all eight CDIP-58 subscales, particularly head and neck symptoms (−31.0) and psychosocial functioning (−28.2). Employment increased from baseline (55%) to the end of the study (64%), and there was improvement in work productivity. There was a significant (p < 0.0001) reduction in pain measured by the PNRS, from −0.5 post-treatment 1 to −2.4 at end of study. AEs (neck pain, muscular weakness, dysphagia, nausea) were consistent with onabotulinumtoxinA use.Conclusion: These real-world data indicate that after repeated, long-term use, onabotulinumtoxinA continues to be a safe and effective treatment for CD, improving HRQoL and work productivity.Keywords
This publication has 30 references indexed in Scilit:
- A randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin®) in cervical dystoniaJournal of Neural Transmission, 2013
- Efficacy, Tolerability, and Immunogenicity of OnabotulinumtoxinA in a Randomized, Double-Blind, Placebo-Controlled Trial for Cervical DystoniaClinical Neuropharmacology, 2012
- Botulinum toxin assessment, intervention and aftercare for cervical dystonia and other causes of hypertonia of the neck: international consensus statementEuropean Journal of Neurology, 2010
- Effect of cervical dystonia on employment: A retrospective analysis of the ability of treatment to restore premorbid employment statusMovement Disorders, 2009
- Determinants and status of quality of life after long‐term botulinum toxin therapy for cervical dystoniaEuropean Journal of Neurology, 2007
- Comparison of Botulinum Neurotoxin Preparations for the Treatment of Cervical DystoniaClinical Therapeutics, 2007
- CDIP-58 can measure the impact of botulinum toxin treatment in cervical dystoniaNeurology, 2006
- What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using DysportJournal of Neurology, Neurosurgery & Psychiatry, 1998
- Dysphagia after botulinum toxin injections for spasmodic torticollisNeurology, 1992
- Cervical dystoniaNeurology, 1991